What Does the Future Hold for Coronary Artery Revascularization?

Unless otherwise noted, speakers have nothing to disclose.

Moderators

Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Duravena: Consultant (Ongoing); Potrero Med: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); ReValve Med: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Faisal Bakaeen, MD

Presentations

  1. New Guidelines, New Techniques, and the Future of CABG
    Marc Ruel, MD, MPH
    Disclosure: Medtronic: Proctor (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  2. Total arterial multivessel minimally invasive coronary bypass surgery via left lateral mini-thoracotomy: 5 year outcomes
    Piroze M. Davierwala, MD
     
  3. Coronary Revascularization: A Cardiologist's Perspectiv
    Michael Farkouh, MD, MSc
    Disclosure: Amgen: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otitopic: Consultant (Ongoing); Sanofi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)
     
  4. Conduit Choice
    Mario FL Gaudino, MD, PhD, MSCE
     
  5. Panel Discussion
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Activity opens: 
02/01/2023
Activity expires: 
02/01/2026
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Unless otherwise noted, speakers have nothing to disclose.

Moderators

Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Duravena: Consultant (Ongoing); Potrero Med: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); ReValve Med: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Faisal Bakaeen, MD

Presentations

  1. New Guidelines, New Techniques, and the Future of CABG
    Marc Ruel, MD, MPH
    Disclosure: Medtronic: Proctor (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  2. Total arterial multivessel minimally invasive coronary bypass surgery via left lateral mini-thoracotomy: 5 year outcomes
    Piroze M. Davierwala, MD
     
  3. Coronary Revascularization: A Cardiologist's Perspectiv
    Michael Farkouh, MD, MSc
    Disclosure: Amgen: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otitopic: Consultant (Ongoing); Sanofi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)
     
  4. Conduit Choice
    Mario FL Gaudino, MD, PhD, MSCE
     
  5. Panel Discussion